Revance Therapeutics Company Profile (NASDAQ:RVNC)

About Revance Therapeutics

Revance Therapeutics logoRevance Therapeutics, Inc. is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. Its botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. Its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Then, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials. Its TransMTS peptide technology serves various purposes depending on whether it is used in a topical formulation or in an injectable formulation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RVNC
  • CUSIP:
Key Metrics:
  • Previous Close: $14.80
  • 50 Day Moving Average: $15.41
  • 200 Day Moving Average: $15.99
  • 52-Week Range: $12.54 - $42.41
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.81
  • P/E Growth: -0.39
  • Market Cap: $418.71M
  • Outstanding Shares: 28,484,000
  • Beta: 1.31
  • Net Margins: -28,586.33%
  • Return on Equity: -40.44%
  • Return on Assets: -36.60%
  • Debt-to-Equity Ratio: 0.02%
  • Current Ratio: 18.35%
  • Quick Ratio: 18.35%
Additional Links:
Companies Related to Revance Therapeutics:

Analyst Ratings

Consensus Ratings for Revance Therapeutics (NASDAQ:RVNC) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $43.80 (195.95% upside)

Analysts' Ratings History for Revance Therapeutics (NASDAQ:RVNC)
DateFirmActionRatingPrice TargetDetails
8/5/2016Brean CapitalReiterated RatingHoldView Rating Details
6/14/2016SunTrust Banks Inc.Lower Price TargetBuy$46.00 -> $22.00View Rating Details
6/14/2016Piper Jaffray Cos.Reiterated RatingOverweight$54.00 -> $35.00View Rating Details
6/14/2016GuggenheimReiterated RatingBuy$55.00View Rating Details
12/30/2015Cowen and CompanyReiterated RatingBuyView Rating Details
11/10/2015William BlairReiterated RatingBuy$59.00View Rating Details
6/6/2015BMO Capital MarketsReiterated RatingOutperform$24.00 -> $35.00View Rating Details
(Data available from 10/21/2014 forward)


Earnings History for Revance Therapeutics (NASDAQ:RVNC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($0.86)($0.88)$0.06 million$0.80 millionViewN/AView Earnings Details
5/9/2016Q1($0.83)($0.71)$0.08 millionViewListenView Earnings Details
3/2/2016Q415($0.86)($0.83)$0.09 million$0.08 millionViewListenView Earnings Details
11/9/2015Q315($1.01)($0.81)$0.10 million$0.08 millionViewN/AView Earnings Details
8/6/2015Q415($0.84)($0.71)ViewN/AView Earnings Details
5/13/2015Q1($0.69)($0.65)ViewListenView Earnings Details
3/2/2015($0.53)($0.60)ViewN/AView Earnings Details
11/12/2014Q314($0.69)($0.60)ViewN/AView Earnings Details
8/12/2014($0.68)($0.69)ViewN/AView Earnings Details
5/13/2014Q1 14($0.87)($1.93)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Revance Therapeutics (NASDAQ:RVNC)
Current Year EPS Consensus Estimate: $-3.55 EPS
Next Year EPS Consensus Estimate: $-3.08 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.07)($0.66)($0.87)
Q2 20162($0.91)($0.91)($0.91)
Q3 20162($0.95)($0.93)($0.94)
Q4 20162($1.02)($0.95)($0.99)
(Data provided by Zacks Investment Research)


Dividend History for Revance Therapeutics (NASDAQ:RVNC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Revance Therapeutics (NASDAQ:RVNC)
Insider Ownership Percentage: 31.15%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/13/2016Curtis RueggEVPSell1,000$18.25$18,250.00View SEC Filing  
5/9/2016Curtis RueggEVPSell1,000$16.18$16,180.00View SEC Filing  
4/11/2016Curtis RueggEVPSell1,000$19.11$19,110.00View SEC Filing  
3/7/2016Curtis RueggEVPSell1,000$20.43$20,430.00View SEC Filing  
2/8/2016Curtis RueggEVPSell1,000$18.14$18,140.00View SEC Filing  
1/6/2016Curtis RueggEVPSell2,000$33.06$66,120.00View SEC Filing  
11/17/2015Arthur Peter BertolinoEVPSell7,753$39.11$303,219.83View SEC Filing  
8/17/2015Curtis RueggEVPSell3,000$30.33$90,990.00View SEC Filing  
7/17/2015Curtis RueggEVPSell3,000$31.03$93,090.00View SEC Filing  
6/17/2015Curtis RueggEVPSell3,000$33.53$100,590.00View SEC Filing  
5/18/2015Curtis RueggEVPSell3,000$26.42$79,260.00View SEC Filing  
4/17/2015Curtis RueggEVPSell2,000$22.23$44,460.00View SEC Filing  
3/17/2015Curtis RueggEVPSell1,500$18.61$27,915.00View SEC Filing  
3/9/2015Curtis RueggEVPSell500$18.00$9,000.00View SEC Filing  
2/17/2015Curtis RueggEVPSell1,000$16.80$16,800.00View SEC Filing  
1/20/2015Curtis RueggEVPSell1,000$17.25$17,250.00View SEC Filing  
12/17/2014Curtis RueggEVPSell1,000$16.45$16,450.00View SEC Filing  
11/28/2014L Daniel BrowneCEOBuy6,000$16.67$100,020.00View SEC Filing  
11/18/2014Curtis RueggEVPSell1,000$16.00$16,000.00View SEC Filing  
9/17/2014Curtis RueggEVPSell2,000$20.55$41,100.00View SEC Filing  
9/17/2014Jacob WaughInsiderSell97,713$20.73$2,025,590.49View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Revance Therapeutics (NASDAQ:RVNC)
News IconPrice Target & Session Watch on Revance Therapeutics, Inc. (NASDAQ:RVNC) - Recall News (NASDAQ:RVNC) - October 21 at 10:43 AM
News IconNotable Pattern Reporting: Does Revance Therapeutics Inc Have Any Gas After Forming This Multiple Bottom Chart ... - Chester News (NASDAQ:RVNC) - October 17 at 12:20 PM logoRevance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : October 13, 2016 (NASDAQ:RVNC) - October 13 at 10:53 AM
News IconCalifornia State Teachers Retirement System Increases Position in Revance Therapeutics Inc. (RVNC) - DailyQuint (NASDAQ:RVNC) - October 12 at 7:04 PM
News IconToday's Rating Sentiment On Watch: How Many Revance Therapeutics Inc (NASDAQ:RVNC)'s Analysts Are Bearish? - MoneyMakingArticles (NASDAQ:RVNC) - October 8 at 11:38 AM
News IconRevance Therapeutics Inc (RVNC) Updated Broker Price Targets - The De Soto Edge (NASDAQ:RVNC) - September 29 at 12:27 PM
News IconRevance Therapeutics Inc (RVNC) – Broker Update - NewsDen (NASDAQ:RVNC) - September 28 at 12:20 PM
News IconEarnings According to Analysts for Revance Therapeutics, Inc. (NASDAQ:RVNC)? - Frisco Fastball (NASDAQ:RVNC) - September 27 at 11:46 AM
News IconWhat are Research Firms Saying About Revance Therapeutics, Inc. (NASDAQ:RVNC)? - Frisco Fastball (NASDAQ:RVNC) - September 24 at 6:25 PM
News IconStock Tracker: Earnings & Estimates for Revance Therapeutics, Inc. (NASDAQ:RVNC) - Frisco Fastball (NASDAQ:RVNC) - September 17 at 6:37 PM logoRevance Therapeutics, Inc. – Value Analysis (NASDAQ:RVNC) : September 14, 2016 (NASDAQ:RVNC) - September 14 at 7:17 PM
News IconWhat are Brokerage Firms Saying About Revance Therapeutics, Inc. (NASDAQ:RVNC)? - Frisco Fastball (NASDAQ:RVNC) - September 14 at 11:31 AM logoRevance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : September 13, 2016 (NASDAQ:RVNC) - September 13 at 11:59 AM logoETF’s with exposure to Revance Therapeutics, Inc. : August 31, 2016 (NASDAQ:RVNC) - August 31 at 12:25 PM logoRevance to Participate in the 2016 Wells Fargo Securities Healthcare Conference (NASDAQ:RVNC) - August 30 at 7:03 PM logoRevance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : August 30, 2016 (NASDAQ:RVNC) - August 30 at 10:26 AM logoNew Market Report: Revance Therapeutics, Inc. (RVNC) - Financial and Strategic SWOT Analysis Review (NASDAQ:RVNC) - August 24 at 6:55 PM logoREVANCE THERAPEUTICS, INC. Financials (NASDAQ:RVNC) - August 16 at 7:21 PM logoETF’s with exposure to Revance Therapeutics, Inc. : August 15, 2016 (NASDAQ:RVNC) - August 15 at 7:36 PM logoRevance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : August 12, 2016 (NASDAQ:RVNC) - August 12 at 10:26 AM logoRevance Therapeutics, Inc. :RVNC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:RVNC) - August 10 at 7:43 PM logoEdited Transcript of RVNC earnings conference call or presentation 4-Aug-16 8:30pm GMT (NASDAQ:RVNC) - August 5 at 7:29 PM logoREVANCE THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:RVNC) - August 5 at 7:29 PM
News IconRevance Releases Second Quarter 2016 Results (NASDAQ:RVNC) - August 5 at 10:14 AM logoNew Broker Ratings For Revance Therapeutics Inc (RVNC) - FTSE News (NASDAQ:RVNC) - August 4 at 7:43 PM logoRevance reports 2Q loss (NASDAQ:RVNC) - August 4 at 7:43 PM logoQ2 2016 Revance Therapeutics Inc Earnings Release - After Market Close (NASDAQ:RVNC) - August 4 at 10:26 AM logoRevance Therapeutics Inc (RVNC) Updated Price Targets - FTSE News (NASDAQ:RVNC) - July 25 at 7:22 PM logoShareholder Alert: Sohmer Law Firm Investigating Revance Therapeutics, Inc. (NASDAQ:RVNC) - July 25 at 10:46 AM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Revance Therapeutics, Inc. (NASDAQ:RVNC) - TGP (NASDAQ:RVNC) - July 21 at 7:35 PM
News IconAre Analysts Bullish Revance Therapeutics Inc (NASDAQ:RVNC) After Last Week? - Consumer Eagle (NASDAQ:RVNC) - July 21 at 7:35 PM logoRevance Therapeutics Inc. (RVNC) Drops 6.81% on July 19 - (NASDAQ:RVNC) - July 21 at 7:35 PM logoRevance Therapeutics Inc (NASDAQ:RVNC) Stock Technicals at Critical Inflection Point - CML News (NASDAQ:RVNC) - July 21 at 7:35 PM logoRevance Therapeutics to Release Second Quarter 2016 Financial Results Thursday, August 4, 2016 (NASDAQ:RVNC) - July 21 at 4:05 PM
News IconIs Selling Revance Therapeutics Inc Here a Winning Strategy? - Consumer Eagle (NASDAQ:RVNC) - July 20 at 10:06 AM
News IconRevance Therapeutics, Inc. (NASDAQ:RVNC): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:RVNC) - July 20 at 10:06 AM
News IconTrading Performance and Target Watch for Revance Therapeutics, Inc. (NASDAQ:RVNC) - Press Telegraph (NASDAQ:RVNC) - July 18 at 12:48 PM logoThese 5 Stocks Are Primed for Breakouts (NASDAQ:RVNC) - July 15 at 2:38 PM logoRevance Therapeutics (RVNC) Completes Pre-Phase 3 Meeting with FDA for RT002 Injectable - (NASDAQ:RVNC) - July 15 at 12:28 PM
News IconCrowd Rating and Earnings Recap for Revance Therapeutics, Inc. (NASDAQ:RVNC) - Telanagana Press (NASDAQ:RVNC) - July 14 at 7:29 PM
News IconEye on Stock Volatility for: Revance Therapeutics, Inc. (NASDAQ:RVNC) - Engelwood Daily (NASDAQ:RVNC) - July 14 at 7:29 PM logo4:03 pm Revance Therapeutics announces it is moving forward with an IND submission for phase 3 clinical program for RT002 & other supportive studies required for the BLA filing after its pre-phase meeting with the FDA (NASDAQ:RVNC) - July 14 at 4:03 PM logoRevance Announces Completion of Pre-Phase 3 Meeting with FDA for RT002 Injectable to Treat Glabellar Lines (NASDAQ:RVNC) - July 14 at 4:02 PM
News IconHow Analysts Feel About Revance Therapeutics Inc (NASDAQ:RVNC)? - Press Telegraph (NASDAQ:RVNC) - July 13 at 10:06 AM
News IconRevance Therapeutics Incorporated (NASDAQ:RVNC) Sellers Increased By 11.1% Their Shorts - Engelwood Daily (NASDAQ:RVNC) - July 9 at 10:19 AM
News IconNASDAQ:RVNC Stockholder Notice: Investigation of potential Wrongdoing at Revance Therapeutics Inc (NASDAQ:RVNC) - July 7 at 10:00 AM
News IconStock Moving in on a Recent Low: Revance Therapeutics, Inc. (NASDAQ:RVNC) - Press Telegraph (NASDAQ:RVNC) - July 6 at 7:35 PM logoRevance Therapeutics Inc. (RVNC) Drops 5.21% on July 05 - (NASDAQ:RVNC) - July 6 at 7:35 PM
News IconHow Analysts Rated Revance Therapeutics Inc (NASDAQ:RVNC) Last Week? - Press Telegraph (NASDAQ:RVNC) - July 5 at 6:56 PM


Revance Therapeutics (NASDAQ:RVNC) Chart for Friday, October, 21, 2016

Last Updated on 10/21/2016 by Staff